Edition:
United States

CEL-SCI Corp (CVM.A)

CVM.A on American Stock Exchange

1.87USD
20 Oct 2017
Change (% chg)

$0.07 (+3.85%)
Prev Close
$1.80
Open
$1.80
Day's High
$1.91
Day's Low
$1.79
Volume
61,913
Avg. Vol
22,387
52-wk High
$7.45
52-wk Low
$1.46

Latest Key Developments (Source: Significant Developments)

Sabby Management reports 7.40 oct passive stake in CEL-SCI Corp
Wednesday, 23 Aug 2017 12:47pm EDT 

Aug 23 (Reuters) - Cel-sci Corp :Sabby Management LLC reports 7.40 percent passive stake in CEL-SCI Corp ‍​as of August 23 - sec filing.  Full Article

CEL-SCI announces $3.5 mln registered direct offering
Wednesday, 23 Aug 2017 09:00am EDT 

Aug 23 (Reuters) - CEL-SCI Corp :CEL-SCI announces $3.5 million registered direct offering.CEL-SCI Corp - ‍intends to use net proceeds from offering for Phase 3 clinical study and general corporate purposes​.CEL-SCI Corp - in connection with offering, CEL-SCI to issue about 1.8 million registered shares of common stock at a purchase price of $2.00 per share.  Full Article

FDA removes clinical hold on Cel-Sci head & neck cancer trial
Monday, 14 Aug 2017 07:00am EDT 

Aug 14 (Reuters) - Cel-Sci Corp :U.S. FDA removes clinical hold on Cel-Sci's Phase 3 head & neck cancer trial.Cel-Sci Corp - ‍study's 928 patients are being monitored and continue to be followed for protocol-specific outcomes​.Cel-Sci - ‍received a letter from U.S. FDA stating that clinical hold that had been imposed on co's phase 3 cancer study with multikine​ has been removed.Cel-Sci - ‍determination if study's primary end point has been met will occur when there are 298 deaths in two specific groups​.Says FDA letter states ‍all clinical trial activities under the investigational new drug application may resume​.  Full Article

CEL-SCI Corp reports Q3 loss per share $0.53
Wednesday, 9 Aug 2017 04:20pm EDT 

Aug 10 (Reuters) - CEL-SCI Corp -:CEL-SCI Corporation reports third quarter fiscal year 2017 financial results.Q3 loss per share $0.53.  Full Article

CEL-SCI Corp extends expiration date of its series DD warrants
Thursday, 6 Jul 2017 07:30am EDT 

July 6 (Reuters) - CEL-SCI Corp :CEL-SCI Corp - extending expiration date of its series DD warrants by one month, from July 10, 2017 to August 10, 2017.  Full Article

CEL-SCI receives letter from U.S. FDA
Thursday, 29 Jun 2017 05:15pm EDT 

June 29 (Reuters) - CEL-SCI Corp ::Says on June 28, received a letter from U.S. FDA in response to most recent June 2 submission - SEC filing.CEL-SCI Corp - in letter, FDA requested that three additional changes be made to multikine investigator brochure that co submitted to FDA on June 2.Says FDA provided instructions directing CEL-SCI on what specific changes should be.CEL-SCI Corp says intends to swiftly make requested changes to ib and submit its response to FDA as soon as possible after July 4 holiday.Letter is regarding clinical hold imposed on co's phase 3 head and neck cancer study with multikine investigational new drug.Says FDA did not raise any other hold issues in the recent letter.Says was also told by FDA that effect of hold is not a termination of study.CEL-SCI Corp - CEL-SCI may not enroll new patients and may not resume multikine dosing in any previously enrolled patient in the phase 3 study.CEL-SCI may not initiate any new studies under the multikine investigational new drug.  Full Article

Cel-Sci reports reverse stock split
Monday, 12 Jun 2017 04:00pm EDT 

June 12 (Reuters) - Cel-Sci Corp ::Cel-Sci announces reverse stock split.Cel-Sci Corp - Cel-Sci expects split to be implemented on June 15, 2017.Cel-Sci Corp - a 1-for-25 reverse split was authorized for its outstanding shares of common stock.  Full Article

CEL-SCI submits FDA response for its phase 3 head and neck cancer trial
Monday, 5 Jun 2017 08:00am EDT 

June 5 (Reuters) - CEL-SCI Corp :Cel-SCI submits FDA response for its phase 3 head and neck cancer trial.CEL-SCI Corp - 928 patients have been enrolled, treated, and are now being followed for study's primary endpoint.CEL-SCI - hold issues addressed in FDA communication were that study's investigator brochure (IB) and "dear investigator" letter need to be revised.CEL-SCI Corp - specific deficiencies and their locations in each of documents were identified by FDA as hold issues.CEL-SCI Corp - determination if study end point is met will occur when there are total of 298 deaths in two main comparator groups.  Full Article

Cel-Sci Q2 loss per share $0.05
Wednesday, 10 May 2017 04:30pm EDT 

May 10 (Reuters) - Cel-Sci Corp ::Cel-Sci Corporation reports second quarter fiscal year 2017 financial results.Q2 loss per share $0.05.  Full Article

Cel-Sci announces $1.51 million registered direct offering
Monday, 1 May 2017 08:42am EDT 

May 1 (Reuters) - Cel-sci Corp :Cel-Sci announces $1.51 million registered direct offering.Cel-Sci - entered definitive agreement with one institutional investor for offering of shares of stock with proceeds of about $1.51 million in direct offering.Cel-Sci corp- intends to use net proceeds from offering for phase 3 clinical study and general corporate purposes.  Full Article

BRIEF-Cel-Sci ‍extends expiration date of series DD and series EE warrants​

* Says ‍extended expiration date of its series dd and series ee warrants until close of business on December 1, 2017​